Newleos Therapeutics, a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders, has named Timothy Noyes as its new President and Chief Executive Officer. Mr. Noyes succeeds founding CEO David Donabedian, who will remain with the company in an advisory role.
Aarvik Therapeutics, an antibody-drug conjugate (ADC) biotechnology company, has secured investment from Laurus Labs, India, in its Series Seed 2 financing round. The funding, which also included multiple other investors, will support the advancement of Aarvik’s ADC pipeline. Since its
Leyden Labs, a Dutch biotech company, has secured €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL. The funding will support the clinical development of its pan-influenza nasal spray (PanFlu) and further mucosal platform
Pfizer Inc. has entered into a definitive agreement to acquire Metsera Inc., a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases, for approximately $4.9 billion. The deal, unanimously approved by the Boards of Directors of both companies, includes a
Charles River Laboratories International, Inc. and BioTech Social Inc. have announced the exploration of a potential strategic collaboration aimed at supporting early-stage life sciences companies through investment crowdfunding. If formalised, the partnership would grant participants of the Charles River Incubator
Uniquity Bio, a clinical-stage drug development company backed by Blackstone Life Sciences, has appointed Will Kane as its new President and Chief Executive Officer. The announcement follows the departure of co-founder and former CEO Brian Lortie in June 2025. The
Merck, known as MSD outside the United States and Canada, has announced a definitive agreement to acquire Verona Pharma plc for $107 per American Depository Share, representing a total transaction value of approximately $10 billion. The move strengthens Merck’s cardio-pulmonary
Circio Holding ASA, a biotechnology company focused on circular RNA technology, has expanded its laboratory operations in Stockholm, Sweden. The new facility at Novum Labs will support the company’s advancing circVec RNA platform, particularly in gene and cell therapy applications.
Orano Med, a subsidiary of the Orano Group and a developer of vector-guided internal radiotherapy (VIR), has announced the completion of a major expansion to its research and development centre in Plano, Texas. The expansion adds around 1,000 m² to
64x Bio, a biotechnology company focused on scalable manufacturing solutions for advanced therapies, has announced the launch of its AAV Apex Suite. The new product line is designed to address critical manufacturing challenges in gene therapy by increasing viral vector
